Abstract/Journal Article

DZNE-2020-00697

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png [18F]THK-5351 PET in Patients with Clinically Diagnosed Progressive Supranuclear Palsy

Haglinger, G.DZNE*

2016

Abstract: The pathophysiology of progressive supranuclear palsy (PSP) is characterized by deposition of fibrillar aggregates of 4-repeat tau protein in neurons. These deposits are a key finding leading to the neuropathological diagnosis of “definite PSP”, which is usually established post mortem. The diagnosis of PSP in vivo according to current criteria does not take tau pathology into consideration. In light of future intervention trials biomarkers to establish a molecular diagnosis and also as potential markers of disease progression become increasingly important. [18F]THK-5351 as a novel Tau-PET ligand may allow in vivo visualization and quantification of tau deposits, therefore the aim of the study is to investigate characteristics of [18F]THK-5351 binding in patients with clinically diagnosed PSP and correlate tau-tracer uptake with clinical findings.

---

Contributing Institute(s):

1. München Pre 2020 (München Pre 2020)

Research Program(s):

1. 342 - Disease Mechanisms and Model Systems (POF3-342) (POF3-342)

Appears in the scientific report 2016

---

Database coverage:
; BIOSIS Previews ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---